Reckitt Benckiser fined $1.7m for misleading claims about Nurofen’s ‘pain specific’ relief

Reckitt Benckiser has been ordered to pay a $1.7m fine after being found guilty of misleading consumers with claims Nurofen could target specific pain.

Nurofen Specific Pain products landscapeThe fine is a victory for the Australian Competition and Consumer Commission (ACCC) and for ABC series The Checkout, which called out the misleading branding in a segment broadcast in 2013.

The ACCC launched the action in the Federal Court, which found in a December ruling that the active ingredient in the pain-specific products was no different to that found in standard Nurofen and ordered the products off the shelves.

The company marketed the products as targeting a number of different pains, including back pain, period pain, migraine pain and tension headache.

Be a member to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Become a member

Get the latest media and marketing industry news (and views) direct to your inbox.

Sign up to the free Mumbrella newsletter now.

"*" indicates required fields

 

SUBSCRIBE

Sign up to our free daily update to get the latest in media and marketing.